Robert A Colbert Selected Research

HLA-B27 Antigen (HLA B27 Antigen)

1/2018	Juvenile Spondyloarthritis: A Distinct Form of Juvenile Arthritis.
1/2018	Effects of HLA-B27 on Gut Microbiota in Experimental Spondyloarthritis Implicate an Ecological Model of Dysbiosis.
1/2017	The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.
1/2016	ERAP1 reduces accumulation of aberrant and disulfide-linked forms of HLA-B27 on the cell surface.
6/2015	Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven.
1/2014	HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats.
1/2014	HLA-B27 misfolding and ankylosing spondylitis.
9/2009	HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.
7/2009	Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
1/2009	HLA-B27 misfolding and spondyloarthropathies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert A Colbert Research Topics

Disease

15	Ankylosing Spondylitis 01/2021 - 02/2004
11	Arthritis (Polyarthritis) 01/2021 - 06/2002
11	Inflammation (Inflammations) 12/2020 - 07/2008
8	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2022 - 01/2005
4	Spondylarthropathies 01/2009 - 07/2002
3	Sacroiliitis 01/2019 - 05/2012
3	Reactive Arthritis (Reiter Disease) 01/2018 - 07/2004
3	Rheumatic Diseases (Rheumatism) 01/2017 - 07/2012
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2016 - 06/2015
3	Disease Progression 06/2015 - 09/2002
2	VEXAS syndrome 10/2021 - 12/2020
2	Vesicular Stomatitis 01/2021 - 01/2021
2	Uveitis 01/2019 - 01/2019
2	Dysbiosis 01/2018 - 12/2017
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018 - 07/2015
2	Psoriatic Arthritis 10/2017 - 01/2014
2	Iritis 02/2016 - 02/2016
2	Spondylarthritis (Spinal Arthritis) 09/2009 - 01/2007
2	Proteostasis Deficiencies 01/2009 - 01/2009
1	Bone Diseases (Bone Disease) 01/2022
1	Melorheostosis 01/2022
1	Thrombocytopenia (Thrombopenia) 10/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2021
1	Macrocytic Anemia 10/2021
1	Multiple Myeloma 10/2021
1	Lymphopenia (Lymphocytopenia) 10/2021
1	COVID-19 01/2021
1	Axial Spondyloarthritis 01/2021
1	Dermatomyositis (Dermatopolymyositis) 01/2021
1	Crohn Disease (Crohn's Disease) 01/2020
1	Tracheomalacia 12/2019
1	Cryopyrin-Associated Periodic Syndromes 12/2015
1	Bone Resorption 06/2015
1	Anterior Uveitis 01/2014
1	Pain (Aches) 12/2012
1	Pharyngitis (Sore Throat) 04/2011
1	Aphthous Stomatitis (Aphthous Ulcer) 04/2011
1	Fever (Fevers) 04/2011
1	Lymphadenitis (Adenitis) 04/2011
1	Back Pain (Backache) 12/2010
1	Infections 01/2010
1	Cytokine Release Syndrome 01/2010

Drug/Important Bio-Agent (IBA)

18	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2018 - 06/2002
10	Biological ProductsIBA 01/2022 - 07/2009
7	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 09/2002
5	Monoclonal AntibodiesIBA 01/2021 - 02/2016
4	Interleukin-17 (Interleukin 17)IBA 01/2021 - 07/2008
4	GlucocorticoidsIBA 01/2019 - 02/2016
4	Interleukin-23 (Interleukin 23)IBA 01/2018 - 07/2008
3	Antirheumatic Agents (DMARD)IBA 01/2022 - 07/2009
3	CytokinesIBA 01/2021 - 09/2009
3	Infliximab (Remicade)FDA Link 01/2019 - 09/2002
3	Interleukin-1 (Interleukin 1)IBA 01/2018 - 04/2011
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2016 - 12/2012
2	EnzymesIBA 10/2021 - 12/2020
2	VaccinesIBA 01/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 01/2017
2	Janus Kinase InhibitorsIBA 01/2021 - 10/2017
2	Adalimumab (Humira)FDA Link 01/2019 - 01/2019
2	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 01/2019
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 07/2008
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2008
2	HLA-B Antigens (HLA-B)IBA 12/2017 - 07/2015
2	Proteins (Proteins, Gene)FDA Link 01/2017 - 06/2002
2	AminopeptidasesIBA 01/2016 - 07/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	NucleotidesIBA 01/2022
1	Certolizumab Pegol FDA Link 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	ixekizumabIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	matrigelIBA 01/2022
1	secukinumabIBA 01/2022
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 10/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	baricitinibIBA 01/2021
1	Janus KinasesIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 12/2020
1	AntibodiesIBA 01/2020
1	AntigensIBA 01/2020
1	SteroidsIBA 11/2019
1	LipopolysaccharidesIBA 11/2019
1	PropionatesIBA 11/2019
1	RNA (Ribonucleic Acid)IBA 01/2018
1	InterferonsIBA 01/2018
1	16S Ribosomal RNAIBA 01/2018
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 12/2015
1	InterleukinsIBA 08/2014
1	chlorotriphenylsilane (CTPS)IBA 07/2014
1	Mutant Proteins (Protein, Mutant)IBA 07/2012
1	Indicators and Reagents (Reagents)IBA 01/2010
1	Interleukin-10 (Interleukin 10)IBA 07/2009
1	Rheumatoid FactorIBA 07/2009

Therapy/Procedure

6	Therapeutics 01/2022 - 07/2008
2	Arthroplasty 02/2016 - 02/2016
2	Physical Therapy Modalities (Physical Therapy Technique) 02/2016 - 02/2016
1	Tracheostomy 12/2019
1	Injections 01/2018